These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30455596)

  • 1. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.
    Sennesael AL; Larock AS; Douxfils J; Elens L; Stillemans G; Wiesen M; Taubert M; Dogné JM; Spinewine A; Mullier F
    Thromb J; 2018; 16():28. PubMed ID: 30455596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
    Škorňová I; Samoš M; Bolek T; Kamenišťáková A; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e122-e127. PubMed ID: 34173805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
    Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
    Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of
    Wang Y; Chen M; Chen H; Wang F
    Front Pharmacol; 2021; 12():639854. PubMed ID: 33935730
    [No Abstract]   [Full Text] [Related]  

  • 5. Target Drug-Calibrated Anti-Xa Activity Assays and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study.
    Liu Z; Xie Q; Zhang H; Mu G; Zhou S; Wang Z; Jiang J; Xiang Q; Cui Y
    Am J Cardiovasc Drugs; 2021 Nov; 21(6):669-679. PubMed ID: 34142346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.
    Lähteenmäki J; Vuorinen AL; Pajula J; Harno K; Lehto M; Niemi M; van Gils M
    Clin Pharmacol Ther; 2021 Sep; 110(3):768-776. PubMed ID: 34043814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.
    Sennesael AL; Panin N; Vancraeynest C; Pochet L; Spinewine A; Haufroid V; Elens L
    Sci Rep; 2018 Jul; 8(1):10514. PubMed ID: 30002384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study.
    Cavaillez T; Weinmann L; Mouton C; Delassasseigne C; Sesay M; Biais M; James C; Roullet S
    Thromb Res; 2021 Oct; 206():76-83. PubMed ID: 34419866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Paoletti O; Legnani C; Dellanoce C; Antonucci E; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G
    J Thromb Haemost; 2018 May; 16(5):842-848. PubMed ID: 29532628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
    von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
    Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.
    Testa S; Legnani C; Antonucci E; Paoletti O; Dellanoce C; Cosmi B; Pengo V; Poli D; Morandini R; Testa R; Tripodi A; Palareti G;
    J Thromb Haemost; 2019 Jul; 17(7):1064-1072. PubMed ID: 31013383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.
    Ballerie A; Nguyen Van R; Lacut K; Galinat H; Rousseau C; Pontis A; Nédelec-Gac F; Lescoat A; Belhomme N; Guéret P; Mahé G; Couturaud F; Jégo P; Gouin-Thibault I
    Thromb Res; 2021 Dec; 208():39-44. PubMed ID: 34689080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
    Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
    Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
    Schellings MW; Boonen K; Schmitz EM; Jonkers F; van den Heuvel DJ; Besselaar A; Hendriks JG; van de Kerkhof D
    Thromb Res; 2016 Mar; 139():128-34. PubMed ID: 26916310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
    Yoshio T; Tomida H; Iwasaki R; Horiuchi Y; Omae M; Ishiyama A; Hirasawa T; Yamamoto Y; Tsuchida T; Fujisaki J; Yamada T; Mita E; Ninomiya T; Michitaka K; Igarashi M
    Dig Endosc; 2017 Sep; 29(6):686-694. PubMed ID: 28295638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
    Wiesen MHJ; Blaich C; Taubert M; Jennissen V; Streichert T; Pfister R; Michels G
    Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways.
    Huppertz A; Grond-Ginsbach C; Dumschat C; Foerster KI; Burhenne J; Weiss J; Czock D; Purrucker JC; Rizos T; Haefeli WE
    BMC Pharmacol Toxicol; 2019 Aug; 20(1):53. PubMed ID: 31464657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.